JP2021512910A - ノボビオシン類似体とプロリンとの共結晶形態 - Google Patents

ノボビオシン類似体とプロリンとの共結晶形態 Download PDF

Info

Publication number
JP2021512910A
JP2021512910A JP2020542665A JP2020542665A JP2021512910A JP 2021512910 A JP2021512910 A JP 2021512910A JP 2020542665 A JP2020542665 A JP 2020542665A JP 2020542665 A JP2020542665 A JP 2020542665A JP 2021512910 A JP2021512910 A JP 2021512910A
Authority
JP
Japan
Prior art keywords
proline
crystal
crystal according
powder
ray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020542665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512910A5 (https=
Inventor
シン ジャン
シン ジャン
ジョン アレン ウォーリング
ジョン アレン ウォーリング
メラニー ジェイ． ベヴィル
メラニー ジェイ． ベヴィル
クリストファー エス． シーディーク
クリストファー エス． シーディーク
ジャレド ピー． スミット
ジャレド ピー． スミット
Original Assignee
リアタ ファーマシューティカルズ インコーポレイテッド
リアタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リアタ ファーマシューティカルズ インコーポレイテッド, リアタ ファーマシューティカルズ インコーポレイテッド filed Critical リアタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2021512910A publication Critical patent/JP2021512910A/ja
Publication of JP2021512910A5 publication Critical patent/JP2021512910A5/ja
Priority to JP2023173340A priority Critical patent/JP2024001167A/ja
Priority to JP2025178611A priority patent/JP2026012851A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020542665A 2018-02-07 2019-02-01 ノボビオシン類似体とプロリンとの共結晶形態 Pending JP2021512910A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023173340A JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023173340A Division JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A Division JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Publications (2)

Publication Number Publication Date
JP2021512910A true JP2021512910A (ja) 2021-05-20
JP2021512910A5 JP2021512910A5 (https=) 2022-02-04

Family

ID=65444361

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542665A Pending JP2021512910A (ja) 2018-02-07 2019-02-01 ノボビオシン類似体とプロリンとの共結晶形態
JP2023173340A Withdrawn JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A Pending JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023173340A Withdrawn JP2024001167A (ja) 2018-02-07 2023-10-05 ノボビオシン類似体とプロリンとの共結晶形態
JP2025178611A Pending JP2026012851A (ja) 2018-02-07 2025-10-23 ノボビオシン類似体とプロリンとの共結晶形態

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR102718111B1 (https=)
CN (2) CN118894894A (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI868593B (https=)
WO (1) WO2019156907A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401294B2 (en) 2018-02-07 2022-08-02 Reata Pharmaceuticals, Inc. Co-crystal forms of a novobiocin analog and proline

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143890A1 (en) * 2011-12-06 2013-06-06 F.I.S. Fabbrica Italiana Sintetici S.P.A. Co-crystal intermediates of rosuvastatin and methods of using same
JP2014513693A (ja) * 2011-05-09 2014-06-05 ヤンセン ファーマシューティカ エヌ．ベー． （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（３−（（５−（４−フルオロフェニル）チオフェン−２−イル）メチル）−４−メチルフェニル）−６−（ヒドロキシメチル）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールのｌ−プロリン及びクエン酸との共結晶
JP2015506982A (ja) * 2012-02-09 2015-03-05 ユニバーシティ・オブ・カンザス Ｃ末端Ｈｓｐ９０阻害剤
JP2017530107A (ja) * 2014-09-30 2017-10-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013006651A2 (pt) * 2010-09-23 2017-07-18 Nuformix Ltd composição e cocristal de aprepitante l-prolina
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
ES2671478T3 (es) * 2012-08-31 2018-06-06 Novartis Ag Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
CN106536498A (zh) * 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺
IL276583B2 (en) 2018-02-07 2025-03-01 Reata Pharmaceuticals Inc Crystal structures of proline and a novobiocin analog

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513693A (ja) * 2011-05-09 2014-06-05 ヤンセン ファーマシューティカ エヌ．ベー． （２ｓ，３ｒ，４ｒ，５ｓ，６ｒ）−２−（３−（（５−（４−フルオロフェニル）チオフェン−２−イル）メチル）−４−メチルフェニル）−６−（ヒドロキシメチル）テトラヒドロ−２ｈ−ピラン−３，４，５−トリオールのｌ−プロリン及びクエン酸との共結晶
US20130143890A1 (en) * 2011-12-06 2013-06-06 F.I.S. Fabbrica Italiana Sintetici S.P.A. Co-crystal intermediates of rosuvastatin and methods of using same
JP2015506982A (ja) * 2012-02-09 2015-03-05 ユニバーシティ・オブ・カンザス Ｃ末端Ｈｓｐ９０阻害剤
JP2017530107A (ja) * 2014-09-30 2017-10-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHARM TECH JAPAN, vol. 25, no. 12, JPN6013060384, 2009, pages 155 - 166, ISSN: 0005075044 *
TILBORG, A. ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 74, JPN6021017265, 2014, pages 411 - 426, ISSN: 0005075045 *
平山 令明 編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0004952912 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401294B2 (en) 2018-02-07 2022-08-02 Reata Pharmaceuticals, Inc. Co-crystal forms of a novobiocin analog and proline
JP2024001167A (ja) * 2018-02-07 2024-01-09 リアタ ファーマシューティカルズ インコーポレイテッド ノボビオシン類似体とプロリンとの共結晶形態

Also Published As

Publication number Publication date
JP2026012851A (ja) 2026-01-27
SG11202007530XA (en) 2020-09-29
AR114245A1 (es) 2020-08-12
CA3090646A1 (en) 2019-08-15
AU2022283638B2 (en) 2024-07-25
CL2020002051A1 (es) 2021-02-19
CN112020506A (zh) 2020-12-01
IL276583B2 (en) 2025-03-01
US20240043465A1 (en) 2024-02-08
US11401294B2 (en) 2022-08-02
CN118894894A (zh) 2024-11-05
KR102718111B1 (ko) 2024-10-17
IL276583A (en) 2020-09-30
IL276583B1 (en) 2024-11-01
JP2024001167A (ja) 2024-01-09
PE20211446A1 (es) 2021-08-05
CA3090646C (en) 2024-02-27
TWI868593B (zh) 2025-01-01
TW202510893A (zh) 2025-03-16
WO2019156907A1 (en) 2019-08-15
TWI797249B (zh) 2023-04-01
EA202091885A1 (ru) 2021-01-15
CA3226385A1 (en) 2019-08-15
IL315865A (en) 2024-11-01
EP3749675A1 (en) 2020-12-16
AU2019217821B2 (en) 2022-09-08
CN112020506B (zh) 2024-10-11
US10717755B2 (en) 2020-07-21
AU2022283638A1 (en) 2023-02-02
US20190241599A1 (en) 2019-08-08
MX2020008326A (es) 2020-09-28
BR112020016205A2 (pt) 2020-12-15
KR20240155354A (ko) 2024-10-28
MY209803A (en) 2025-08-05
TW201945381A (zh) 2019-12-01
EP3749675B1 (en) 2025-12-31
CO2020009761A2 (es) 2020-10-30
AU2019217821A1 (en) 2020-09-24
MX2022012856A (es) 2022-11-30
NZ767558A (en) 2024-11-29
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CL2022003784A1 (es) 2023-06-09
AU2024227646A1 (en) 2024-11-14
US20200347088A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
TWI482778B (zh) 結晶型式之製備方法
JP2024001167A (ja) ノボビオシン類似体とプロリンとの共結晶形態
EP3903785B1 (en) Cocrystal of phosphoric acid and a mc1r agonsist
CN112638904A (zh) 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式
KR20200115661A (ko) 노르이보가인 염 무용매화물
CN105143194A (zh) 依洛昔巴特的结晶修饰物
US20120309695A1 (en) Crystalline form of linaclotide
JP2024546844A (ja) ピラゾロ［３，４－ｄ］ピリミジン化合物の固体形態
US10301344B2 (en) L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof
TWI915111B (zh) 新生黴素（ｎｏｖｏｂｉｏｃｉｎ）類似物及脯胺酸之共晶型
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
WO2026024591A1 (en) Tryptamine prodrug solid forms
HK40068368B (zh) 索吡溴铵的晶型及其制备方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260312